Barbara Seliger Selected Research

Histocompatibility Antigens Class I

8/2020	Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma.
1/2020	HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease.
12/2019	Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
1/2019	Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display.
1/2017	Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.
1/2017	Modulation of MHC class I surface expression in B16F10 melanoma cells by methylseleninic acid.
1/2014	B7-H abnormalities in melanoma and clinical relevance.
5/2013	The prognostic impact of human leukocyte antigen (HLA) class I antigen abnormalities in salivary gland cancer. A clinicopathological study of 288 cases.
8/2012	Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer.
8/2012	The role of classical and non-classical HLA class I antigens in human tumors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Barbara Seliger Research Topics

Disease

167	Neoplasms (Cancer) 01/2022 - 05/2002
41	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 05/2002
31	Melanoma (Melanoma, Malignant) 01/2022 - 05/2002
15	Breast Neoplasms (Breast Cancer) 01/2020 - 01/2004
13	Neoplasm Metastasis (Metastasis) 08/2020 - 02/2004
12	Carcinoma (Carcinomatosis) 01/2022 - 09/2005
11	Disease Progression 01/2022 - 03/2006
7	Carcinogenesis 07/2020 - 01/2004
5	Infections 01/2022 - 09/2005
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2021 - 09/2005
5	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 03/2004
5	Squamous Cell Carcinoma of Head and Neck 01/2021 - 04/2005
4	Virus Diseases (Viral Diseases) 01/2022 - 01/2006
4	Lung Neoplasms (Lung Cancer) 11/2021 - 02/2020
3	Inflammation (Inflammations) 01/2022 - 12/2014
3	Hypoxia (Hypoxemia) 08/2016 - 05/2015
3	Prostatic Neoplasms (Prostate Cancer) 08/2014 - 10/2009
3	Adenocarcinoma 08/2012 - 03/2004
3	Ovarian Neoplasms (Ovarian Cancer) 10/2009 - 11/2003
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2012 - 02/2007
2	Leukemia 04/2012 - 04/2005
2	Lymphatic Metastasis 09/2004 - 03/2004
1	Urologic Neoplasms (Urological Cancer) 01/2022

Drug/Important Bio-Agent (IBA)

31	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2002
31	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2003
27	Histocompatibility Antigens Class IIBA 08/2020 - 05/2003
21	AntigensIBA 01/2020 - 05/2002
19	HLA-G Antigens (HLA G)IBA 01/2022 - 02/2003
18	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2011
18	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 07/2003
15	CytokinesIBA 01/2022 - 03/2004
14	LigandsIBA 01/2022 - 05/2009
14	Peptides (Polypeptides)IBA 01/2020 - 05/2002
12	AntibodiesIBA 06/2020 - 03/2004
9	ProteomeIBA 05/2014 - 12/2002
8	Immune Checkpoint InhibitorsIBA 01/2022 - 08/2016
8	Messenger RNA (mRNA)IBA 01/2022 - 10/2003
7	Surface Antigens (Surface Antigen)IBA 08/2020 - 06/2006
7	tapasinIBA 01/2020 - 05/2003
7	HLA-A Antigens (HLA-A)IBA 12/2019 - 10/2009
6	VaccinesIBA 01/2022 - 12/2002
6	RNA (Ribonucleic Acid)IBA 03/2021 - 01/2017
6	Neoplasm Antigens (Tumor Antigens)IBA 01/2021 - 05/2002
6	DNA (Deoxyribonucleic Acid)IBA 11/2020 - 08/2002
6	InterferonsIBA 01/2020 - 05/2002
6	Small Interfering RNA (siRNA)IBA 09/2019 - 01/2004
5	Amino Acids FDA Link 11/2020 - 10/2003
5	Biological ProductsIBA 07/2020 - 10/2004
5	Monoclonal AntibodiesIBA 01/2019 - 08/2012
4	Transcription Factors (Transcription Factor)IBA 10/2020 - 10/2014
4	EpitopesIBA 01/2019 - 06/2003
4	Pharmaceutical PreparationsIBA 01/2015 - 12/2011
4	HLA-A2 Antigen (HLA A2 Antigen)IBA 01/2011 - 06/2006
3	Programmed Cell Death 1 ReceptorIBA 01/2022 - 04/2016
3	Complement System Proteins (Complement)IBA 01/2021 - 03/2009
3	BiglycanIBA 01/2021 - 01/2018
3	Carrier Proteins (Binding Protein)IBA 10/2020 - 08/2016
3	RNA-Binding Proteins (RNA-Binding Protein)IBA 07/2020 - 01/2020
3	Hormones (Hormone)IBA 01/2020 - 12/2019
3	Cyclic AMP Response Element-Binding Protein (Cyclic AMP-Responsive DNA-Binding Protein)IBA 01/2020 - 11/2013
3	transporter associated with antigen processing (TAP)IBA 01/2020 - 05/2003
3	EnzymesIBA 01/2019 - 03/2003
3	Peptide Hydrolases (Proteases)FDA Link 01/2018 - 10/2008
3	Lactic Acid (Lactate)FDA LinkGeneric 11/2016 - 05/2011
3	Mitogen-Activated Protein KinasesIBA 11/2015 - 12/2013
3	HLA-DR Antigens (HLA-DR)IBA 06/2015 - 05/2011
3	Interleukin-4 (Interleukin 4)IBA 05/2014 - 03/2004
3	UbiquitinIBA 12/2013 - 01/2007
3	HydrolasesIBA 12/2013 - 01/2007
2	Histocompatibility Antigens Class IIIBA 08/2021 - 01/2017
2	Member 2 Subfamily B ATP Binding Cassette TransporterIBA 08/2020 - 01/2020
2	Formaldehyde (Formol)FDA Link 01/2020 - 05/2003
2	ParaffinIBA 01/2020 - 08/2012
2	Glycoproteins (Glycoprotein)IBA 11/2019 - 04/2005
2	Extracellular Matrix ProteinsIBA 01/2018 - 01/2018
2	Fibronectins (Fibronectin)IBA 01/2018 - 01/2018
2	Natural Cytotoxicity Triggering Receptor 1IBA 01/2018 - 01/2018
2	ElementsIBA 11/2017 - 08/2016
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 03/2017 - 06/2003
2	ChemokinesIBA 04/2016 - 04/2016
2	Glucose (Dextrose)FDA LinkGeneric 05/2015 - 05/2011
2	micaIBA 10/2014 - 03/2012
2	Complementary DNA (cDNA)IBA 05/2014 - 03/2009
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2013 - 04/2005
2	ErbB Receptors (EGF Receptor)IBA 12/2013 - 10/2012
2	AminopeptidasesIBA 01/2013 - 08/2010
2	Phosphotransferases (Kinase)IBA 03/2012 - 05/2011
2	PerforinIBA 05/2011 - 07/2003
2	DNA VaccinesIBA 05/2009 - 03/2004
2	Codon (Codons)IBA 02/2007 - 03/2004
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2005 - 05/2002
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2005 - 05/2002
2	Interferon-gamma (Interferon, gamma)IBA 10/2003 - 07/2003

Therapy/Procedure

49	Immunotherapy 01/2022 - 06/2003
43	Therapeutics 01/2022 - 06/2003
6	Drug Therapy (Chemotherapy) 12/2019 - 01/2007
3	Transplantation 12/2013 - 05/2009
2	Cell- and Tissue-Based Therapy (Cell Therapy) 02/2021 - 01/2018
2	Radiotherapy 11/2015 - 04/2015
2	Ligation 04/2012 - 10/2011